Core Viewpoint - Haier Biomedical has received a report from Qindao Jiushi Investment Management Co., indicating that Jiushi Youxuan No. 1 Fund plans to increase its stake in the company by 15,897,909 shares, representing 5.00% of the total share capital, due to a long-term positive outlook on the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [1][2]. Group 1 - Jiushi Youxuan No. 1 Fund is currently the second-largest circulating shareholder of Yinkang Life, showcasing its strategic focus on the medical technology sector and recognition of Haier Biomedical's solid fundamentals and clear growth logic [2]. - Haier Biomedical, a leader in low-temperature storage equipment in the biomedical sector, achieved a net profit of 143 million yuan in the first half of 2025, with new industry revenue accounting for 47% of total revenue, driving performance growth [2]. - The company has established a collaborative development framework across four major industries: low-temperature storage, smart medication, blood technology, and laboratory solutions, with significant market shares in various segments [2]. Group 2 - Haier Group, the actual controller of Haier Biomedical, has recently formed a comprehensive strategic partnership with Ant Group to promote the digital upgrade of healthcare services, positioning Haier Biomedical for new growth opportunities [3]. - The investment from Jiushi Youxuan No. 1 Fund is seen as a recognition of Haier Biomedical's technological barriers and growth potential, which may boost investor confidence and provide stronger momentum for the company's long-term development [3].

Core Viewpoint - The announcement details that Qingdao Jiushi Investment Management Co., Ltd. has increased its stake in Haier Biomedical to 5% without triggering a mandatory takeover bid [2][3]. Group 1: Shareholding Changes - Jiushi Youxuan No. 1 Private Securities Investment Fund acquired 15,897,909 shares of Haier Biomedical from August 14, 2024, to October 14, 2025, representing 5% of the total share capital [4][10]. - The increase in shareholding does not change the company's controlling shareholder or actual controller [3][5]. Group 2: Investment Rationale - The investment is based on confidence in the future development of the life sciences industry and recognition of Haier Biomedical's governance, industry position, business capabilities, operational results, and risk management [10]. - Jiushi Youxuan No. 1 has no current plans to increase or decrease its stake in the next 12 months [11]. Group 3: Compliance and Reporting - The report complies with relevant laws and regulations, including the Securities Law and the Management Measures for the Acquisition of Listed Companies [7][12]. - The report confirms that the information disclosed is accurate and complete, with no misleading statements or omissions [12].

Core Viewpoint - Haier Biomedical has been targeted for a stake acquisition by Jiushi Investment, reaching a 5% shareholding threshold, indicating confidence in the company's future development and potential for collaborative growth [1][4][2]. Group 1: Investment Details - Jiushi Investment's Jiushi Preferred No. 1 Fund acquired 15,897,900 shares of Haier Biomedical, representing 5% of the total share capital [4]. - The investment was made through secondary market transactions and was funded by Jiushi Investment's own capital [4]. - Jiushi Investment has no immediate plans to increase or decrease its stake in Haier Biomedical within the next 12 months [4]. Group 2: Company Background - Haier Biomedical is a subsidiary of Haier Group's health ecosystem brand, established in October 2005 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [7]. - The company has faced a continuous decline in stock price over the past four years, with significant drops of 29.83%, 35.46%, 12%, and 6.38% in the years 2022, 2023, 2024, and 2025 respectively [10]. Group 3: Financial Performance - In the first half of 2025, Haier Biomedical reported revenue of 1.196 billion yuan, a decrease of 2.27% year-on-year, and a net profit of 143 million yuan, down 39.09% year-on-year [8]. - The company attributes the profit decline to external factors, new capacity ramp-up, and strategic investments, but anticipates improvement as industry conditions recover [8]. - The overseas business showed strong growth, with revenue of 427 million yuan, a year-on-year increase of 30.17%, achieving the highest quarterly revenue and growth rate since 2023 in the second quarter [9].

Core Viewpoint - The report outlines the equity change of Qingdao Haier Biomedical Co., Ltd. (referred to as "Haier Biomedical") due to an increase in shareholding by Qingdao Jiushi Investment Management Co., Ltd. through its fund Jiushi Preferred No. 1, which acquired 15,897,909 shares, representing 5% of the total share capital of the company, from August 14, 2024, to October 14, 2025 [8][15]. Group 1: Information Disclosure Obligations - The information disclosure obligations are based on the Securities Law of the People's Republic of China and related regulations, ensuring that the report covers all changes in shareholding [1]. - The information disclosure obligor confirms that the report does not contain any false records, misleading statements, or significant omissions, and assumes legal responsibility for its authenticity and completeness [2]. Group 2: Purpose and Future Plans of Equity Change - The purpose of the equity change is driven by a long-term positive outlook on the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [5]. - There are currently no explicit plans or agreements for increasing or decreasing shareholding in the next 12 months, and any future changes will be disclosed in accordance with relevant laws and regulations [7]. Group 3: Details of Equity Change - From August 14, 2024, to October 14, 2025, Jiushi Preferred No. 1 increased its shareholding in Haier Biomedical by 15,897,909 shares, funded by its own capital [8]. - Following this equity change, Jiushi Preferred No. 1 has become a shareholder holding more than 5% of the company's shares [9]. Group 4: Impact on Company Control - The equity change will not alter the controlling shareholder or actual controller of Haier Biomedical [16].

10月15日晚间，海尔生物发布公告称，在本次增持以后，青岛久实投资管理有限公司（以下简称久实投资）旗下久实优选1号私募证券投资基金（以下简 称久实优选1号）拥有权益的股份数量及占公司总股本的比例为5%，达到举牌线。 值得注意的是，海尔生物股价已经连续调整4年左右。国资背景的久实投资此时出手举牌，公司表示意在未来发展中实现协同共赢。 久实投资为国资背景私募公司 资料显示，久实投资是山东青岛本地的私募基金公司，成立于2018年6月4日，注册资本为1000万元；公司于2019年5月20日完成私募证券投资基金管理人 登记，公司管理规模区间是10亿元至20亿元。 | 基金管理人全称(中文) | 青岛久实投资管理有限公司 | | --- | --- | | 基金管理人全称(英文) | | | 登记编号 | P1069779 | | 组织机构代码 | 91370212MA3MFHAUXL | | 登记时间 | 2019-05-20 | | 成立时间 | 2018-06-04 | | 注册地址 | 山东省青岛市崂山区苗岭路9号 | | 办公地址 | 山东省青岛市市南区香港西路48号海天中心T2 | | 注册资本(万元)(人民 ...

Core Viewpoint - The announcement details that Qingdao Jiushi Investment Management Co., Ltd. has increased its stake in Qingdao Haier Biomedical Co., Ltd. to 5% through market transactions, reflecting confidence in the company's future development and long-term investment value [2][4]. Group 1: Shareholding Changes - Jiushi Youxuan No. 1 Private Securities Investment Fund acquired 15,897,909 shares of Haier Biomedical, representing 5% of the total share capital, between August 14, 2024, and October 14, 2025 [4][14]. - The increase in shareholding does not trigger a mandatory tender offer [2][5]. - The change in shareholding will not alter the company's controlling shareholder or actual controller [3][5]. Group 2: Investment Rationale - The investment is based on the belief in the future prospects of the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [11]. - The funding for the share acquisition comes from Jiushi Youxuan's own capital [4][14]. Group 3: Future Plans - As of the report's signing date, there are no specific plans or agreements for further increasing or decreasing the stake in the next 12 months [13].

【导读】海尔生物被久实优选1号私募证券投资基金举牌 中国基金报记者 吴君 10月15日晚间，海尔生物发布公告称，在本次增持以后，青岛久实投资管理有限公司（以下简称久实投 资）旗下久实优选1号私募证券投资基金（以下简称久实优选1号）拥有权益的股份数量及占公司总股本 的比例为5%，达到举牌线。 值得注意的是，海尔生物股价已经连续调整4年左右。国资背景的久实投资此时出手举牌，公司表示意 在未来发展中实现协同共赢。 久实投资举牌海尔生物 海尔生物最新发布公告称，2025年10月15日，公司收到久实投资（代表"久实优选1号"）发来的《简式 权益变动报告书》，基于对公司未来发展前景的信心和对公司长期投资价值的认可，久实优选1号于 2024年8月14日至2025年10月14日通过二级市场集中竞价和大宗交易方式增持公司股份1589.79万股，占 公司总股本的5.00%。 | 基金名称 | 基金备案编号 | 久实优选1号私募证券投资基金 SJD567 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 信息披露 义务人基 | | | | | | | | 基金管理人名称 ...

Core Viewpoint - Haier Biomedical has been targeted by Qindao Jiushi Investment Management Co., Ltd. through its private equity fund, Jiushi Preferred No. 1, which has acquired a 5% stake in the company, marking a significant investment after four years of stock price decline [2][4][12]. Group 1: Investment Details - Jiushi Preferred No. 1 acquired 15,897,909 shares of Haier Biomedical, representing 5% of the total share capital, through secondary market transactions from August 14, 2024, to October 14, 2025 [4][6]. - The investment was made using self-owned funds, and there are no immediate plans to increase or decrease the stake in the next 12 months [6][8]. Group 2: Company Background - Haier Biomedical is a subsidiary of Haier Group's health ecosystem brand, Yingkang Yisheng, established in October 2005 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [13]. - The company has faced a continuous decline in stock price over the past four years, with significant drops of 29.83%, 35.46%, 12%, and 6.38% in 2022, 2023, 2024, and 2025 respectively [12][14]. Group 3: Financial Performance - In the first half of 2025, Haier Biomedical reported revenue of 1.196 billion yuan, a year-on-year decrease of 2.27%, and a net profit attributable to shareholders of 143 million yuan, down 39.09% year-on-year [14]. - The company noted that its new industries are growing well, contributing to 47% of total revenue, with significant growth in overseas business, which saw a 30.17% increase year-on-year [14].

【导读】海尔生物被久实优选1号私募证券投资基金举牌 中国基金报记者 吴君 10月15日晚间，海尔生物发布公告称，在本次增持以后，青岛久实投资管理有限公司（以下 简称久实投资）旗下久实优选1号私募证券投资基金（以下简称久实优选1号）拥有权益的股 份数量及占公司总股本的比例为5%，达到举牌线。 值得注意的是，海尔生物股价已经连续调整4年左右。国资背景的久实投资此时出手举牌，公 司表示意在未来发展中实现协同共赢。 久实投资举牌海尔生物 海尔生物最新发布公告称，2025年10月15日，公司收到久实投资（代表"久实优选1号"）发 来的《简式权益变动报告书》，基于对公司未来发展前景的信心和对公司长期投资价值的认 可，久实优选1号于2024年8月14日至2025年10月14日通过二级市场集中竞价和大宗交易方 式增持公司股份1589.79万股，占公司总股本的5.00%。 | | 基金名称 基金备案编号 | 久实优选 1 号私募证券投资基金 SJD567 | | | | | --- | --- | --- | --- | --- | --- | | 信息披露 义务人基 本信息 | | | | | | | | 基金管理人名称 | ...

Group 1: Company Announcements - Tianpu Co. announced that its stock will resume trading on October 16 after completing an investigation into unusual trading activity, with a significant price increase of 317.72% over 15 consecutive trading days [1] - Haiguang Information reported a third-quarter net profit of 760 million yuan, a year-on-year increase of 13.04%, driven by a 69.6% increase in revenue [1] - Tailing Microelectronics expects a net profit of approximately 140 million yuan for the first three quarters, a year-on-year increase of about 118%, supported by strong sales of new AI chips and other products [2] Group 2: Financial Performance - Guanghua Technology achieved a third-quarter net profit of 34.13 million yuan, a year-on-year increase of 962.19%, with total revenue of 762 million yuan, up 14.99% [3] - JiuZhou Pharmaceutical reported a third-quarter net profit growth of 42.3% [5] - HeSheng New Materials anticipates a net profit increase of 60% to 80% for the first three quarters [5] Group 3: Investment and Partnerships - China Ruilin plans to participate in establishing a mining fund with a total scale of 2 billion yuan, focusing on rare metals such as tungsten and rare earths [4] - Zhenyang Development signed a strategic cooperation framework agreement with Ningbo Graphene Innovation Center [7] - Liying Intelligent Manufacturing intends to increase investment in its subsidiary Vietnam Guanghong by 11.025 million USD [7]